Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05426707
Other study ID # RIC-Resistant HTN
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 1, 2022
Est. completion date March 30, 2023

Study information

Verified date September 2022
Source Capital Medical University
Contact Xunming Ji, MD, PhD
Phone 83199430
Email jixm@ccmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to explore the efficacy and safety of remote ischemia adaptation for the treatment of resistant hypertension.


Description:

Resistant hypertension is defined as a blood pressure of 140/90 mmHg or higher despite adherence to at least three antihypertensive drugs (including one diuretic), accounting for 20% to 30% of patients with hypertension. Compared with patients with well-controlled blood pressure, the cardiovascular risk of resistant hypertension is increased by about 50%. Limb remote ischemic conditioning (LRIC) triggers endogenous protective effects through transient and repeated ischemia in the limb to protect remote tissues and organs. The mechanisms of LRIC involve the regulation of the autonomic nervous system, the release of humoral factors, improvement of vascular endothelial function, and modulation of immune/inflammatory responses, which can antagonize the pathogenesis of hypertension through multiple pathways to lead to a drop in BP theoretically. This theory has been preliminarily confirmed by several small sample-size studies in non-resistant hypertension. This study aims to explore the efficacy and safety of remote ischemia adaptation for the treatment of resistant hypertension.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date March 30, 2023
Est. primary completion date February 1, 2023
Accepts healthy volunteers No
Gender All
Age group 30 Years to 80 Years
Eligibility Inclusion Criteria: - Aged 30~80 years old; - Taking = 3 antihypertensive drugs (including one diuretic) for more than 4 weeks regularly; - Office blood pressure = 140/90mmhg, and 24 h average blood pressure = 130/80 mmHg; - Willing to participate in the study, follow the study protocol, and provide informed consent. Exclusion Criteria: - Secondary hypertension; - eGFR<45ml/min/1.73m2; - Office blood pressure =180/110 mmHg, and 24 h average blood pressure = 170/100 mmHg; - Hypertensive crisis occurred within 3 months; - Type 1 diabetes; - Cardiovascular events occurred within 3 months; - Atrial fibrillation; - Presence of any severe disease that adversely affects the subject or study; - Patients with contraindication for remote ischemic conditioning, such as vascular injury, soft tissue injury, orthopedic injury, or arm infection; - Pregnancy, lactation, or planned pregnancy; - Patients not suitable for this trial considered by researchers for other reasons; - Participation in another device or drug trial simultaneously.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
RIC
RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
Sham-RIC
The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ji Xunming,MD,PhD

Outcome

Type Measure Description Time frame Safety issue
Primary Changes of 24 h average systolic blood pressure Changes of 24 h average systolic blood pressure from baseline to 8 weeks from baseline to 8 weeks
Secondary Changes of 24 h average diasolic blood pressure Changes of 24 h average diasolic blood pressure from baseline to 8 weeks from baseline to 8 weeks
Secondary Changes of daytime average systolic blood pressure Changes of daytime average systolic blood pressure from baseline to 8 weeks from baseline to 8 weeks
Secondary Changes of daytime average diastolic blood pressure Changes of daytime average diastolic blood pressure from baseline to 8 weeks from baseline to 8 weeks
Secondary Changes of nighttime average systolic blood pressure Changes of nighttime average systolic blood pressure from baseline to 8 weeks from baseline to 8 weeks
Secondary Changes of nighttime average diastolic blood pressure Changes of nighttime average diastolic blood pressure from baseline to 8 weeks from baseline to 8 weeks
Secondary Changes of 24 h average heart rate Changes of 24 h average heart rate from baseline to 8 weeks from baseline to 8 weeks
Secondary Changes of office systolic blood pressure Changes of office systolic blood pressure from baseline to 8 weeks from baseline to 8 weeks
Secondary Changes of office diastolic blood pressure Changes of office diastolic blood pressure from baseline to 8 weeks from baseline to 8 weeks
Secondary Changes of home systolic blood pressure Changes of home systolic blood pressure from baseline to 8 weeks from baseline to 8 weeks
Secondary Changes of home diastolic blood pressure Changes of home diastolic blood pressure from baseline to 8 weeks from baseline to 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05545059 - Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension Phase 3
Not yet recruiting NCT04388124 - VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION Phase 2
Withdrawn NCT01939392 - Rapid Renal Sympathetic Denervation for Resistant Hypertension II Phase 2/Phase 3
Recruiting NCT06228677 - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting NCT04213963 - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Recruiting NCT05563077 - Aerobic Exercise and Resistant Hypertension N/A
Recruiting NCT03758196 - Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH) N/A
Active, not recruiting NCT03179800 - CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™ N/A
Completed NCT04519658 - A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) Phase 2
Not yet recruiting NCT05552300 - Superselective Adrenal Arterial Embolization for Resistant Hypertension N/A
Completed NCT04345198 - Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension N/A
Active, not recruiting NCT05562934 - An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. Phase 2
Recruiting NCT06034743 - A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Phase 3
Withdrawn NCT02926495 - Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension. N/A
Active, not recruiting NCT02670681 - Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects N/A
Completed NCT02572024 - The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study) N/A
Terminated NCT02295683 - Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
Completed NCT02001350 - Carotid Ultrasound Study N/A
Recruiting NCT04331691 - Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension Phase 4
Recruiting NCT04637152 - Sacubitril/Valsartan in Resistant Hypertension Phase 2